Purple Biotech (PPBT) has released an update.
Purple Biotech has unveiled promising data for its innovative CAPTN-3 antibody platform, which targets triple-negative breast cancer and non-small cell lung cancer. This tri-specific technology engages both T cells and NK cells, demonstrating sustained tumor regression and a favorable safety profile. The company’s lead compound, IM1240, highlights the platform’s potential to revolutionize cancer treatment by targeting various solid tumors.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
